Home › Funds › OBERWEIS ASSET MANAGEMENT INC/ › ARQT
OBERWEIS ASSET MANAGEMENT INC/ position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
OBERWEIS ASSET MANAGEMENT INC/ reported holding 1,372,941 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$36.0M, representing 0.74% of its reported portfolio and ranking #39 among its reported holdings. OBERWEIS ASSET MANAGEMENT INC/ has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How OBERWEIS ASSET MANAGEMENT INC/'s ARQT position evolved
OBERWEIS ASSET MANAGEMENT INC/ first disclosed a stake in ARQT in Q4 2025 at 808,400 shares (US$23.5M). The position peaked in Q2 2026 at 1,372,941 shares, worth US$36.0M. Across 3 filings, OBERWEIS ASSET MANAGEMENT INC/ increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,372,941 shares valued at US$36.0M — an increase of 7,000 shares quarter over quarter.. Notable position changes include a 69% increase in Q1 2026 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 808.40K | $23.48M | New |
| Q1 2026 | 1.37M | $32.18M | Add |
| Q2 2026 | 1.37M | $36.00M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Jones Hill Capital LP 1.09M sh · $28.57M · Q2 2026
- FISHMAN JAY A LTD/MI 595.00K sh · $15.60M · Q2 2026
More on OBERWEIS ASSET MANAGEMENT INC/
FAQ
How long has OBERWEIS ASSET MANAGEMENT INC/ held ARQT?
OBERWEIS ASSET MANAGEMENT INC/ has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is OBERWEIS ASSET MANAGEMENT INC/'s current position in ARQT?
As of Q2 2026, OBERWEIS ASSET MANAGEMENT INC/ holds 1.37M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $36.00M, representing 0.74% of its reported portfolio and ranking #39.
Has OBERWEIS ASSET MANAGEMENT INC/ been buying or selling ARQT?
In the latest 13F filing (Q2 2026), OBERWEIS ASSET MANAGEMENT INC/ increased its position in ARQT. The position peaked in Q2 2026 at 1.37M shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.